Appendix1 from A Phase 2 Trial of RANKL Antibody, Denosumab, in Two Cohorts of Patients with Recurrent/Refractory Osteosarcoma, a Report from the Children’s Oncology Group
Authors:
- Katherine A. JanewayKJKatherine A. Janeway
- Alexander J. ChouACAlexander J. Chou
- Allen BuxtonABAllen Buxton
- Joel ReidJRJoel Reid
- Michael S. IsakoffMIMichael S. Isakoff
- Lisa KoppLKLisa Kopp
- Pooja HingoraniPHPooja Hingorani
- Jill L. LeeJLJill L. Lee
- John DoskiJDJohn Doski
- Heike Daldrup-LinkHDHeike Daldrup-Link
- Laura HallLHLaura Hall
- R. Lor RandallRRR. Lor Randall
Open Access
- 6 January 2026
- other
- Published by American Association for Cancer Research (AACR)